home / stock / amyt / amyt news

AMYT News and Press, Amryt Pharma plc From 11/03/22

Stock Information
Company Name: Amryt Pharma plc
Stock Symbol: AMYT
Market: NASDAQ
Website: amrytpharma.com
Menu
AMYT AMYT Quote AMYT Short AMYT News AMYT Articles AMYT Message Board
Get AMYT Alerts

News, Short Squeeze, Breakout and More Instantly...
AMYT - Amryt Pharma GAAP EPS of -$0.06, revenue of $61.1M, reaffirms FY guidance

Amryt Pharma press release ( NASDAQ: AMYT ): Q3 GAAP EPS of -$0.06. Revenue of $61.1M (+8.1% Y/Y). FY 2022 revenue guidance of $260M - $270M reaffirmed, representing 17-21% growth over 2021 For further details see: Amryt Pharma GAAP EPS of -$0.06, revenue of ...
AMYT - Amryt Reports Q3 2022 Financial and Operational Results

Amryt Reports Q 3 2022 Financial and Operational Results 8. 2 % YoY revenue growth in Q 3 to $ 6 1 . 1 M - 12.5% on a const...

AMYT - Amryt Supports Acromegaly Awareness Day 2022

Amryt Supports Acromegaly Awareness Day 202 2 DUBLIN, Ireland, and Boston MA, October 31 , 202 2 , Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing...

AMYT - The British Journal of Dermatology Publishes Results from Amryt's EASE Phase 3 Trial in Epidermolysis Bullosa

The British Journal of Dermatology Publishes Results f rom Amryt’s EASE Phase 3 Trial in Epidermolysis Bullosa DUBLIN, Ireland, and Boston MA, October 2 5 , 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical...
AMYT - Amryt Supports Global EB Awareness Week 2022

Amryt Supports Global EB Awareness Week 202 2 DUBLIN, Ireland, and Boston MA, Octo ber 2 4 , 202 2 , Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercia...

AMYT - Amryt to Report Q3 2022 Results on November 3, 2022

A mryt to Report Q 3 202 2 Results on November 3 , 2022 DUBLIN, Ireland, and Boston MA, October 19 , 202 2 , Amryt (Nasdaq: AMYT ) a global, commercial-stage...

AMYT - Amryt gets EMA panel nod for Mycapssa to retain orphan drug status in EU

A committee of the European Medicines Agency (EMA) recommended that the orphan disease designation to Amryt's ( NASDAQ: AMYT ) Mycapssa to treat acromegaly in the EU is maintained. Acromegaly is a disorder characterized by the pituitary gland producing too much gr...
AMYT - COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly

COMP adopts positive opinion on O rphan D isease D esignation for Mycapssa® for the treatment of Acromegaly DUBLIN, Ireland, and Boston MA, October 18 , 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company d...

AMYT - Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)

Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin) DUBLIN, Ireland, and Boston MA, Oct o ber 1 7 , 202 2 , Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical com...

AMYT - Amryt Supports FH Awareness Day - September 24, 2022

Amryt Supports FH Awareness Day – September 24, 202 2 DUBLIN, Ireland, and Boston MA, September 2 3 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializi...
Previous 10 Next 10